Shirley Palmer - Concepedia

Author

Shirley Palmer

Detroit Receiving Hospital

Also Known As

Gerald Langman, S M Palmer, S Palmer, S. M. Palmer, S. Palmer, Shirley M. Palmer, Shirley Palmer

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Detroit Receiving Hospital The Francis Crick Institute CRUK Lung Cancer Centre of Excellence University College London London Cancer

About

Shirley Palmer is an author at Detroit Receiving Hospital specializing in medicine, drug resistance, and clinical microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	293
2	Health Sciences	5	5	194
3	Microbiology	4	4	121
4	Cell Biology	1	1	99
5	Pathology	1	1	99

Shirley Palmer

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution Nicholas McGranahan, Rachel Rosenthal, Crispin T. Hiley, Cell	2017	1.3K
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors Frederick Arce Vargas, Andrew J.S. Furness, Isabelle Solomon, Immunity	2017	425
Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections Jill James, Shirley Palmer, Donald P. Levine, Antimicrobial Agents and Chemotherapy	1996	144
The T cell differentiation landscape is shaped by tumour mutations in lung cancer Ehsan Ghorani, James L. Reading, Jake Y. Henry, Nature Cancer Somatic VariantTumor HeterogeneityMedicineTumour MutationsPathology	2020	99
Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model Diane M. Cappelletty, Sangrim Kang, Shirley Palmer, Antimicrobial Agents and Chemotherapy Antimicrobial SusceptibilityHealth SciencesMedicineAtcc 27853Pharmacotherapy	1995	73
Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model Shirley Palmer, Sangrim Kang, Diane M. Cappelletty, Antimicrobial Agents and Chemotherapy Klebsiella PneumoniaeStaphylococcus AureusAntimicrobial ChemotherapyAntibiotic ResistanceNew Injectable Cephalosporin	1995	55
Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots Shirley Palmer, Michael J. Rybak Antimicrobial Agents and Chemotherapy	1996	35
Vancomycin‐Resistant Enterococci Shirley Palmer, Michael J. Rybak Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy Antimicrobial ChemotherapyAntibiotic ResistanceDrug ResistanceAntimicrobial StewardshipAntimicrobial Therapy	1996	26
An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots Shirley Palmer Journal of Antimicrobial Chemotherapy Time-kill CurvesBactericidal ActivityInfected Fibrin ClotsAntimicrobial ChemotherapyHomogeneous Strain	1997	20
Vancomycin‐Resistant Enterococci Michael J. Rybak, Shirley Palmer Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy Antimicrobial SusceptibilityVancomycin RestrictionsAntibioticsHealth SciencesMedicine	1995	20

Page 1